Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565643 | 0.90 | RIPK1 (0.45) | HCRTR2HCRTR1RIPK1ACACBGPBAR1 | |
| SCHEMBL20565035 | 0.86 | RIPK1 (0.42) | HCRTR2HCRTR1RIPK1ACACBGPBAR1 | |
| SCHEMBL26121359 | 0.80 | PPARG (0.43) | ACACBCHRM4 | |
| SCHEMBL31340035 | 0.78 | RIPK1 (0.40) | HCRTR2HCRTR1RIPK1ACACBGPBAR1 | |
| SCHEMBL31340034 | 0.77 | RIPK1 (0.39) | HCRTR2HCRTR1RIPK1GPBAR1SLC6A9 | |
| SCHEMBL20565239 | 0.74 | RIPK1 (0.47) | HCRTR2HCRTR1RIPK1ACACBSLC6A9 | |
| SCHEMBL18255044 | 0.73 | KDM4E (0.57) | HCRTR2RIPK1 | |
| SCHEMBL31038865 | 0.73 | PDE10A (0.50) | — | |
| SCHEMBL19652157 | 0.70 | CKS1B (0.52) | RIPK1 | |
| SCHEMBL20064248 | 0.70 | CKS1B (0.54) | DRD2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285572-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119264073-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | HCRTR2 4856/4885HCRTR1 4870/4885RIPK1 353/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | HCRTR2 4856/4885HCRTR1 4870/4885RIPK1 353/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | HCRTR2 4856/4885HCRTR1 4870/4885RIPK1 353/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | HCRTR2 4856/4885HCRTR1 4870/4885RIPK1 353/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | HCRTR2 4856/4885HCRTR1 4870/4885RIPK1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.